Periodontitis

Reading File

Finding Sources

Searching PubMed

"periodontitis"[MeSH Terms] AND ("treatment" OR "management")

Reading File

Finding Sources

Loading Image

Reading File

I now have comprehensive content from multiple authoritative textbooks. Let me compile the full response.

Periodontitis

Definition

Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth - the periodontal ligament, alveolar bone, and cementum. Unlike gingivitis (which is confined to the marginal gingiva and is reversible), periodontitis involves progressive, largely irreversible destruction of these supporting tissues.

Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 498

Etiology and Microbiology

Periodontitis is a polymicrobial infection primarily involving anaerobic gram-negative organisms derived from subgingival dental plaque. The key pathogens are:

Organism	Notes
Porphyromonas gingivalis	Potent extracellular proteases; disrupts complement
Aggregatibacter (Actinobacillus) actinomycetemcomitans	Produces leukotoxin; implicated in aggressive/juvenile forms
Prevotella intermedia	Associated with adult chronic periodontitis
Treponema denticola	Binds serum factors to interfere with complement deposition

Healthy gingival sites are colonized by facultative gram-positive organisms
Active periodontitis sites shift to anaerobic and microaerophilic gram-negative flora
Synergistic interactions between P. gingivalis, T. denticola, and other plaque members foster progression from gingivitis to chronic periodontitis
Robbins, Cotran & Kumar, p. 498-499; Sherris & Ryan's Medical Microbiology, p. 1509

Pathogenesis

The sequence of events:

Dental plaque accumulation - a sticky biofilm of bacteria, salivary proteins, and epithelial cells collects in the gingival sulcus (subgingival plaque)
Gingivitis - polymorphonuclear leukocytes, lymphocytes, and plasma cells infiltrate connective tissue adjacent to the gingival crevice; collagen is lost; this is reversible
Progression to periodontitis - with continued inflammation, alveolar bone resorption begins; the sulcus deepens into a periodontal pocket
Periodontal pocket deepening - creates a more anaerobic environment favoring pathogenic gram-negative flora
Ligament destruction - periodontal ligament attachment is lost; teeth loosen
Tooth loss - the endpoint if untreated; chronic periodontitis is the leading cause of tooth loss in adults >35-40 years

Key virulence mechanisms:

P. gingivalis proteases degrade collagen and tissue proteins
T. denticola evades complement
Bacterial Toll-like receptor (TLR) interactions trigger dysregulated host inflammatory responses
Sherris & Ryan's Medical Microbiology, p. 1509-1510

Clinical Presentation

Periodontitis showing plaque, inflammatory changes, bleeding, and gingival shortening between teeth

Advanced chronic periodontitis: plaque, inflammatory changes, bleeding, and recession of the interdental papillae (Sherris & Ryan's Medical Microbiology, Fig. 41-5B)

Clinical features include:

Gingival erythema, edema, bleeding on probing
Periodontal pocket formation (probing depth >3 mm)
Gingival recession, exposed root surfaces
Tooth mobility and drifting
Halitosis
Eventual tooth loss if untreated

Disease progression is typically episodic - acute exacerbations separated by quiescent periods.

Classification

Type	Features
Chronic (adult) periodontitis	Most common; slow progression; adults >35 years; closely linked to P. gingivalis, P. intermedia, T. denticola
Localized aggressive periodontitis	Adolescents; rapid loss of attachment; associated with A. actinomycetemcomitans leukotoxin
Generalized aggressive periodontitis	Young adults; widespread rapid bone loss
Necrotizing periodontal disease	Immunocompromised patients (HIV, poorly controlled diabetes); fusospirochetal organisms; painful ulcerative lesions with tissue necrosis

A periodontal abscess can occur when a periodontal pocket becomes constricted, bacteria proliferate, and an acute inflammatory response develops within the occluded pocket.

Systemic Associations

Periodontitis is associated with a spectrum of systemic conditions:

Immunodeficiency: AIDS, neutrophil deficiency or dysfunction
Metabolic: Diabetes mellitus (bidirectional relationship - diabetes worsens periodontitis; periodontitis worsens glycemic control)
Inflammatory: Crohn disease, sarcoidosis, Down syndrome
Autoimmune: Rheumatoid arthritis (infection and smoking promote citrullination of self-proteins, contributing to RA pathogenesis)
Cardiovascular: Periodontal bacteria may seed infective endocarditis
Infectious: Periodontal bacteria can cause abscesses in the lungs and brain
Robbins, Cotran & Kumar, p. 500

Special note - HIV: Periodontal disease in HIV follows a staging:

Linear gingival erythema - fiery red band disproportionate to plaque
Necrotizing ulcerative gingivitis/periodontitis/stomatitis - progressive recession, bleeding, tissue sloughing, pain, malodor, loss of interdental papillae

K.J. Lee's Essential Otolaryngology, p. 239

Investigations

Dental probing - measures pocket depth (>3 mm = periodontitis)
Dental X-rays / CT - assesses extent of alveolar bone resorption
In necrotizing disease or new presentation: blood glucose and HIV testing
If bony destruction is disproportionate to mucosal injury: biopsy to exclude malignancy or bacillary angiomatosis

Management

Non-Surgical (First-line)

Intervention	Details
Oral hygiene	Twice-daily brushing and flossing
Scaling and root planing	Mechanical debridement of subgingival plaque and calculus (mainstay of treatment)
Chlorhexidine rinse	0.12-0.2% preferred antibacterial rinse
Hydrogen peroxide	3% diluted 1:1 with warm water (alternative)
Smoking cessation	Most important modifiable risk factor in HIV-negative patients
Analgesia	Ibuprofen 400-600 mg q6-8h or acetaminophen 650 mg q6h; topical viscous lidocaine for severe local pain

Antibiotics (for severe disease, immunocompromise, or systemic symptoms)

Antibiotic	Dose	Duration
Penicillin V	500 mg TID-QID	10 days
Amoxicillin/clavulanate	500/125 mg TID (or 875/125 mg)	10 days
Metronidazole	500 mg BID (penicillin allergy)	10 days
Clindamycin	300 mg QID (penicillin allergy)	10 days
Nystatin	100,000 units/mL, 5 mL swish/spit QID	10 days (immunocompromised)

Rosen's Emergency Medicine, p. 2720-2721

Necrotizing Disease

Dentist-performed debridement of necrotic tissue
Systemic antimicrobials
In HIV: chlorhexidine + nystatin mouthwash (covers bacterial and fungal etiologies)

Surgical Options (refractory/advanced disease)

Flap surgery for access to deeper pockets
Bone grafting and guided tissue regeneration
Tooth extraction when irreversibly compromised

Recent Evidence (2024-2026)

Recent systematic reviews note:

Probiotics as adjuncts to non-surgical treatment show some benefit in reducing pocket depth (PMID: 39407177)
PRP and injectable PRF as adjuncts in non-surgical treatment have emerging supportive evidence (PMID: 38928026)
Electronic cigarette use is associated with worse periodontal outcomes - similar to conventional smoking (PMID: 39385155)

Key Points Summary

Periodontitis = irreversible destruction of tooth-supporting structures (bone + ligament + cementum)
The shift from gram-positive to gram-negative anaerobic flora is central to pathogenesis
The "red complex" pathogens (P. gingivalis, T. denticola, T. forsythia) drive chronic disease
Not reversible - lost bone does not regenerate; treatment halts progression
Strong bidirectional links with diabetes, cardiovascular disease, and RA make it a systemic disease concern
First-line treatment is mechanical (scaling/root planing) ± antibiotics for severe cases

Cirrhosis long answer in detail according to medicine Pathophysiology in flowchart form, clincial features system wise and also types of cirrhosis and their pathogenesis

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Loading Image

I now have everything needed for a comprehensive answer. Let me compose it.

CIRRHOSIS - Detailed Long Answer

1. DEFINITION

Cirrhosis is the end-stage of any chronic liver disease, defined histopathologically as diffuse architectural distortion of the liver by fibrous bands that subdivide the hepatic parenchyma into regenerative nodules. It is characterized by:

Irreversible (largely) destruction of normal liver architecture
Fibrous replacement of hepatic parenchyma
Formation of regenerative nodules
Portosystemic vascular shunting

"Regardless of the cause of cirrhosis, the pathologic features consist of the development of fibrosis to the point that there is architectural distortion with the formation of regenerative nodules."

Harrison's Principles of Internal Medicine 22E

2. ETIOLOGY / CAUSES

Category	Specific Causes
Alcohol	Alcoholic liver disease (~48% of cirrhosis deaths)
Viral hepatitis	Chronic hepatitis B, Chronic hepatitis C
Metabolic	MASLD/NASH (Metabolic dysfunction-associated steatohepatitis)
Biliary	Primary biliary cholangitis (PBC), Primary sclerosing cholangitis (PSC), Biliary atresia, Cystic fibrosis
Autoimmune	Autoimmune hepatitis, Autoimmune cholangiopathy
Metabolic/Genetic	Hemochromatosis, Wilson's disease, Alpha-1 antitrypsin deficiency
Vascular	Budd-Chiari syndrome, Hepatic venous outflow obstruction, Right heart failure (cardiac cirrhosis)
Drugs/Toxins	Methotrexate, amiodarone, intestinal bypass
Cryptogenic	No identifiable cause (~10-15%)

3. MORPHOLOGY

Gross:

Nodular, bumpy liver surface
Depressed areas of scarring alternating with bulging regenerative nodules
May be small/shrunken (late) or enlarged (early/fatty)

Microscopic:

Parenchymal nodules surrounded by dense fibrous bands
Variable nodule size
Fibrous bands linking portal tracts to each other (portal-portal bridging) or portal tracts to central veins (portal-central bridging)
Vascular distortion with portosystemic shunts

Nodule classification by size:

Type	Size	Causes
Micronodular	<3 mm	Alcoholic, hemochromatosis, biliary obstruction
Macronodular	>3 mm	Viral hepatitis, Wilson's disease
Mixed	Both	Late alcoholic (after abstinence), various

4. PATHOPHYSIOLOGY - FLOWCHART

CHRONIC LIVER INJURY (alcohol / virus / fat / autoimmune / metabolic)
          │
          ▼
HEPATOCYTE DAMAGE + INFLAMMATION
(necrosis, apoptosis, Kupffer cell activation → profibrogenic cytokines:
TGF-β, PDGF, TNF-α, IL-1)
          │
          ▼
ACTIVATION OF HEPATIC STELLATE CELLS (Ito cells / perisinusoidal cells)
 • Normally quiescent in space of Disse; store vitamin A (retinoids)
 • On activation: lose vitamin A, proliferate, transform into myofibroblasts
 • Secrete: Collagen types I & III, proteoglycans, glycoproteins
 • Become contractile → vasoconstriction of sinusoids
          │
          ▼
FIBROSIS DEPOSITION IN SPACE OF DISSE
 • "Capillarization" of sinusoids (loss of sinusoidal fenestrae)
 • ↓ Exchange between plasma and hepatocytes
 • ↑ Sinusoidal resistance
          │
          ▼
PROGRESSIVE ARCHITECTURAL DISTORTION
 • Formation of fibrous septa bridging portal-portal and portal-central
 • Hepatocyte regeneration → nodule formation (regenerative nodules)
 • Normal vascular relationships destroyed → portosystemic shunts
          │
          ▼
CIRRHOSIS (end-stage fibrosis)
          │
    ┌─────┴──────┐
    ▼            ▼
PORTAL        LIVER CELL
HYPERTENSION  INSUFFICIENCY
    │            │
    ▼            ▼
(see below)   Jaundice, coagulopathy,
              hypoalbuminemia, encephalopathy

Portal Hypertension - Detailed Mechanism:

CIRRHOSIS
    │
    ├── FIXED COMPONENT
    │   (Fibrous tissue + nodules compressing sinusoids)
    │
    └── FUNCTIONAL COMPONENT
        (↓ Intrahepatic NO → active vasoconstriction by stellate cells)
                │
                ▼
         ↑ SINUSOIDAL RESISTANCE
                │
                ▼
         ↑ PORTAL VENOUS PRESSURE (>12 mmHg)
                │
         ┌──────┴──────────────────────┐
         ▼                             ▼
  SPLANCHNIC VASODILATION          PORTOSYSTEMIC
  (↑ extrahepatic NO)              COLLATERALS
         │                         (esophageal,
         ▼                          gastric, rectal,
  ↓ Effective arterial              caput medusae)
  blood volume                           │
         │                              ▼
         ▼                       VARICEAL BLEEDING
  Activation of RAAS +
  SNS + ADH
         │
         ▼
  Na⁺ and water retention
         │
    ┌────┴─────┐
    ▼          ▼
  ASCITES   HYPONATREMIA
    │
    ▼
 HYPERDYNAMIC CIRCULATION
 (↑ CO, ↓ SVR, ↑ heart rate)
    │
    ▼
SBP / HEPATORENAL SYNDROME

"The paradox in portal hypertension is that a deficiency of NO in the intrahepatic vasculature leads to vasoconstriction and increased resistance, whereas overproduction of NO in the extrahepatic circulation leads to vasodilation and increased portal flow."

Goldman-Cecil Medicine

5. COMPLICATIONS OF CIRRHOSIS - OVERVIEW DIAGRAM

Complications of cirrhosis: Portal hypertension → variceal hemorrhage + ascites (→SBP, →HRS); Liver insufficiency → encephalopathy + jaundice. (Goldman-Cecil Medicine, Fig. 139-2)

6. CLINICAL FEATURES - SYSTEM-WISE

A. General / Constitutional

Fatigue, weakness, anorexia, weight loss
Muscle wasting (sarcopenia)
Fever (due to bacteremia or alcoholic hepatitis)
~40% are asymptomatic until advanced disease

B. Gastrointestinal System

Feature	Mechanism
Right upper quadrant pain	Liver capsule stretching / hepatitis
Nausea, vomiting	Portal hypertension; alcohol toxicity
Anorexia, early satiety	Ascites compressing stomach
Hepatomegaly (early) → small liver (late)	Initially enlarged; shrinks with fibrosis
Splenomegaly	Portal hypertension → venous congestion
Hypersplenism	Splenic sequestration → thrombocytopenia, leukopenia, anemia
Esophageal/gastric varices	Portal-systemic collaterals
Variceal hemorrhage	Variceal rupture - most feared complication
Caput medusae	Periumbilical collateral veins (recanalization of umbilical vein)
Hemorrhoids (anorectal varices)	Portal-systemic collaterals
Peptic ulcers	Increased gastrin, impaired mucosal defense

C. Skin and Integument

Feature	Mechanism
Jaundice / Icterus	Impaired bilirubin conjugation and excretion
Palmar erythema	Hyperestrogenemia → local vasodilation
Spider angiomas (>5 = significant)	Hyperestrogenemia → arterial dilatation; central pulsating arteriole
Pruritus	Cholestasis → bile acid deposition in skin
Leukonychia (white nails)	Hypoalbuminemia
Terry's nails	Distal brown band
Clubbing	Hepatopulmonary syndrome
Dupuytren's contracture	Fibrosis of palmar fascia (alcohol)
Purpura / bruising	Coagulopathy, thrombocytopenia
Xanthelasma / xanthomata	Cholestasis → altered lipid metabolism (PBC)
Hyperpigmentation	Scratching from pruritus; hemochromatosis
Hair loss	Hormonal disturbance

D. Endocrine / Reproductive System

Feature	Mechanism
Gynecomastia	↑ Estrogen (impaired hepatic metabolism)
Testicular atrophy / hypogonadism	Hyperestrogenemia + hypothalamic-pituitary axis disruption
Loss of body/axillary/pubic hair	Hormonal imbalance
Menstrual irregularity / amenorrhea	Disruption of hypothalamic-pituitary axis
Parotid enlargement	Alcoholic cirrhosis
Diabetes mellitus	Impaired hepatic glucose metabolism ("hepatogenous diabetes")
Hypoglycemia	Reduced glycogen stores

E. Cardiovascular System (Hyperdynamic Circulation)

Feature	Mechanism
↑ Cardiac output	Splanchnic/systemic vasodilation (↑ NO)
↓ SVR	Peripheral vasodilation
Tachycardia	Compensatory
Bounding pulse	Hyperdynamic state
Hepatopulmonary syndrome (HPS)	Intrapulmonary arteriovenous shunts; platypnea-orthodeoxia
Portopulmonary hypertension	Portal hypertension → pulmonary vasoconstriction
Cirrhotic cardiomyopathy	Reduced cardiac contractility despite high output state

F. Respiratory System

Feature	Mechanism
Dyspnea	Ascites → diaphragm elevation; pleural effusion (hepatic hydrothorax); HPS
Hepatic hydrothorax	Passage of ascitic fluid through diaphragmatic defects
Clubbing + cyanosis	HPS (platypnea-orthodeoxia)
Reduced SpO₂ on standing	HPS - improves lying down

G. Renal System

Feature	Mechanism
Ascites	Sinusoidal hypertension + Na⁺ retention (RAAS activation)
Hyponatremia	Free water retention (ADH activation)
Hepatorenal syndrome (HRS)	Renal vasoconstriction from systemic vasodilation; functional renal failure; reversible with liver transplantation
- Type 1 HRS	Rapid progressive renal failure (<2 weeks)
- Type 2 HRS	Slower course; linked to refractory ascites
Proteinuria / hematuria	IgA nephropathy (in alcoholic cirrhosis)

H. Nervous System

Feature	Mechanism
Hepatic encephalopathy (HE)	Portosystemic shunting + liver insufficiency → ammonia and other toxins bypass liver; reach brain
Grade I	Altered sleep, mild confusion, personality change
Grade II	Asterixis (flapping tremor), disorientation
Grade III	Somnolence, stupor, gross disorientation
Grade IV	Coma
Asterixis	Impaired motor inhibition; seen in Grade II HE
Peripheral neuropathy	Nutritional deficiency (B1, B12, folate); alcohol toxicity
Wernicke-Korsakoff syndrome	Thiamine (B1) deficiency in alcoholic cirrhosis

I. Hematological System

Feature	Mechanism
Anemia	Hypersplenism, GI blood loss, nutritional deficiency, bone marrow suppression (alcohol)
Thrombocytopenia	Hypersplenism + reduced thrombopoietin
Leukopenia	Hypersplenism
Coagulopathy (↑PT/INR)	Reduced synthesis of clotting factors II, V, VII, IX, X; factor VII has shortest half-life so affected first
↓ Fibrinogen	Reduced hepatic synthesis
Disseminated intravascular coagulation (DIC) risk	In decompensated cirrhosis

J. Musculoskeletal System

Feature	Mechanism
Sarcopenia (muscle wasting)	Malnutrition, hyperammonemia, hormonal disturbance
Hepatic osteodystrophy	Osteoporosis/osteomalacia from malabsorption of fat-soluble vitamins (D); common in PBC/PSC
Dupuytren's contracture	Palmar fibromatosis (alcohol-related)
Hypertrophic osteoarthropathy	Clubbing and periosteal thickening

7. TYPES OF CIRRHOSIS AND THEIR PATHOGENESIS

A. Alcoholic Cirrhosis

Pathogenesis:

Chronic Alcohol Ingestion
        │
        ▼
Metabolism via:
• ADH → Acetaldehyde
• MEOS (CYP2E1 induction) → ROS + more acetaldehyde
• Catalase (peroxisomal)
        │
        ▼
Acetaldehyde (highly reactive):
• Forms acetaldehyde-protein adducts
• Disrupts microtubular function
• Impairs protein secretion/trafficking
        │
        ▼
Hepatocyte damage + ↑ Triglycerides (steatosis)
↑ ROS → Oxidative membrane damage
        │
        ▼
Kupffer cell activation → TGF-β, TNF-α, IL-1
        │
        ▼
Stellate cell activation → Collagen deposition
        │
        ▼
Centrilobular fibrosis → Pericellular fibrosis → Periportal fibrosis
        │
        ▼
Bridging fibrosis (portal-central) → MICRONODULAR CIRRHOSIS
(nodules <3 mm)

Key features:

Micronodular pattern initially; mixed macro/micronodular after abstinence
Mallory-Denk bodies (cytokeratin inclusions) on histology
AST:ALT ratio typically >2:1 (alcoholic cirrhosis hallmark)
Associated with Zieve's syndrome (hemolytic anemia + jaundice + hyperlipidemia)

B. Viral Cirrhosis (Hepatitis B and C)

Pathogenesis - HBV:

HBV Chronic Infection
        │
        ▼
Direct cytopathic effect + Immune-mediated hepatocyte destruction
(CD8+ T cell attack on HBsAg/HBeAg-expressing hepatocytes)
        │
        ▼
Cycles of necrosis-inflammation-regeneration
        │
        ▼
Progressive portal-portal and portal-central bridging fibrosis
        │
        ▼
MACRONODULAR CIRRHOSIS (nodules >3 mm)
        │
        ▼
↑↑ Risk of HCC (HBV can be directly oncogenic - integrates into genome)

Pathogenesis - HCV:

HCV Chronic Infection
        │
        ▼
Immunological injury (mainly immune-mediated, not direct cytopathic)
Steatosis (especially genotype 3)
        │
        ▼
Periportal inflammation (interface hepatitis)
Lymphoid follicles in portal tracts (HCV hallmark)
        │
        ▼
Periportal fibrosis → Bridging fibrosis → MACRONODULAR CIRRHOSIS
        │
        ▼
↑ HCC risk (requires cirrhosis as intermediary - unlike HBV)

Note: With successful HCV cure (SVR with DAAs), cirrhosis can regress (75% regression at year 5 with TDF in HBV).

C. Biliary Cirrhosis

Two main types:

Primary Biliary Cholangitis (PBC)

Autoimmune attack on intrahepatic bile duct epithelium
(Anti-mitochondrial antibodies - AMA in >95%)
        │
        ▼
Progressive destruction of small/medium intrahepatic bile ducts
(Granulomatous cholangitis - "florid duct lesion")
        │
        ▼
Cholestasis → bile acid accumulation → hepatocyte injury
        │
        ▼
Periportal fibrosis → Portal-portal bridging → CIRRHOSIS

Key features: Middle-aged women; AMA positive; ALP/GGT elevated; pruritus, fatigue, xanthelasma; ↑IgM; treat with UDCA (13-15 mg/kg/day)

Primary Sclerosing Cholangitis (PSC)

Fibro-obliterative inflammation of intra- AND extra-hepatic bile ducts
(Onion-skin periductal fibrosis)
        │
        ▼
"Beaded" appearance on MRCP (strictures alternating with dilatation)
        │
        ▼
Progressive biliary obstruction → BILIARY CIRRHOSIS
        │
        ▼
↑ Risk of cholangiocarcinoma (10-15% lifetime risk)

Key features: Young men; ~80% associated with IBD (UC > Crohn's); pANCA positive; no proven effective medical therapy; liver transplantation definitive.

D. MASLD/NASH Cirrhosis (Metabolic Cirrhosis)

Obesity / Insulin Resistance / Metabolic Syndrome
        │
        ▼
Hepatic steatosis (First Hit: ↑ FFA delivery to liver)
        │
        ▼
Oxidative stress + Mitochondrial dysfunction + Gut dysbiosis
(Second Hit)
        │
        ▼
Lobular inflammation + Hepatocyte ballooning + Mallory-Denk bodies
(Steatohepatitis = NASH)
        │
        ▼
Progressive fibrosis (perisinusoidal/pericellular "chicken-wire" pattern)
        │
        ▼
MACRONODULAR/MIXED CIRRHOSIS
        │
        ▼
↑ HCC risk (can occur even without cirrhosis in MASLD)

E. Cardiac (Congestive) Cirrhosis

Chronic right-sided heart failure / Constrictive pericarditis / 
Tricuspid regurgitation / Budd-Chiari syndrome
        │
        ▼
Hepatic venous outflow obstruction
        │
        ▼
Sinusoidal congestion (centrilobular) → Centrilobular necrosis
"Nutmeg liver" (gross appearance: yellow-red mottling)
        │
        ▼
Pericentral fibrosis → "Reversed lobule" pattern
        │
        ▼
CARDIAC CIRRHOSIS (rare - requires many years)

Key features: Hepatomegaly, pulsatile liver (TR), elevated JVP, peripheral edema preceding ascites; AST/ALT may be very elevated acutely ("shock liver").

F. Metabolic/Genetic Cirrhosis

Hemochromatosis (Hereditary)

HFE gene mutation (C282Y most common) → ↑ GI iron absorption
        │
        ▼
Iron deposition in hepatocytes, Kupffer cells, bile duct epithelium
        │
        ▼
ROS generation → Hepatocyte damage → Fibrosis
        │
        ▼
MICRONODULAR CIRRHOSIS

Triad: Cirrhosis + Diabetes ("bronze diabetes") + Skin pigmentation
↑ Serum ferritin, ↑ Transferrin saturation (>45%)
Treatment: Phlebotomy

Wilson's Disease

ATP7B mutation → ↓ Hepatic copper excretion into bile
        │
        ▼
Copper accumulation → Oxidative liver injury
        │
        ▼
Acute hepatitis → Chronic hepatitis → MACRONODULAR CIRRHOSIS
+ Neuropsychiatric features (basal ganglia) + Kayser-Fleischer rings

Young patients (<40 years)
↓ Serum ceruloplasmin, ↑ Urinary copper, liver biopsy (quantitative copper)

Alpha-1 Antitrypsin Deficiency

PiZZ phenotype → Misfolded AAT accumulates in hepatocytes (ER stress)
(instead of being secreted into blood)
        │
        ▼
Hepatocyte injury → PAS-positive diastase-resistant globules in hepatocytes
        │
        ▼
Progressive fibrosis → CIRRHOSIS
+ Emphysema (↓ AAT in lung → ↑ elastase → alveolar destruction)

8. STAGING AND PROGNOSIS

Child-Turcotte-Pugh (CTP) Score

Parameter	1 point	2 points	3 points
Bilirubin (mg/dL)	<2	2-3	>3
Albumin (g/dL)	>3.5	2.8-3.5	<2.8
PT prolongation (sec)	<4	4-6	>6
Ascites	None	Mild	Moderate-severe
Encephalopathy	None	Grade I-II	Grade III-IV

Class A (5-6 pts): 1-year survival ~100%; compensated
Class B (7-9 pts): 1-year survival ~80%
Class C (10-15 pts): 1-year survival ~45%; decompensated

MELD Score

MELD = 3.78 × ln[Bilirubin] + 11.2 × ln[INR] + 9.57 × ln[Creatinine] + 6.43

Used for organ allocation in liver transplantation
Predicts 90-day mortality

Compensated vs. Decompensated

Compensated	Decompensated
No major complications	Ascites, variceal bleed, encephalopathy, jaundice
Median survival >12 years	Median survival 2 years
Stage 1 & 2	Stage 3 & 4

9. INVESTIGATIONS

Investigation	Finding
LFTs	↑ Bilirubin, ↑ ALP, ↑ GGT; AST & ALT elevated (AST>ALT in alcohol)
Albumin	Low (<3.5 g/dL) - marker of synthetic failure
PT/INR	Prolonged - reduced clotting factor synthesis
CBC	Thrombocytopenia, anemia, leukopenia (hypersplenism)
Serum Na⁺	Hyponatremia in advanced disease
Creatinine	Elevated in HRS
AFP	Elevated in HCC surveillance
Ultrasound	Nodular liver, splenomegaly, ascites, portal vein diameter >13 mm
Doppler	Portal vein flow reversal (hepatofugal) in advanced disease
Upper GI endoscopy	Varices grading
Liver biopsy (gold standard)	Confirms diagnosis; Metavir staging F0-F4
Fibroscan (TE)	Non-invasive liver stiffness measurement (>12.5 kPa = cirrhosis)
HVPG	Hepatic venous pressure gradient (>5 mmHg = portal HTN; >12 mmHg = varices/ascites risk)

10. MANAGEMENT SUMMARY

Complication	Treatment
Ascites	Low-sodium diet + Spironolactone ± Furosemide; therapeutic paracentesis + IV albumin for large-volume ascites
SBP	IV Cefotaxime or Pip-Tazo; secondary prophylaxis with Norfloxacin/Ciprofloxacin
Variceal hemorrhage	Terlipressin/Octreotide; endoscopic band ligation; TIPS; primary prophylaxis: non-selective beta-blockers (propranolol/carvedilol)
HE	Identify precipitant; Lactulose; Rifaximin; low-protein diet (avoid excessive restriction)
HRS	Terlipressin + IV albumin; TIPS; definitive = liver transplantation
Coagulopathy	Vitamin K (if responsive); FFP/cryoprecipitate for active bleeding
HCC	Locoregional therapy (TACE, ablation); sorafenib; liver transplantation (Milan criteria)
Definitive	Liver Transplantation - only cure

Sources:

Harrison's Principles of Internal Medicine 22E, Chapter 355 (Cirrhosis and its Complications)
Goldman-Cecil Medicine International Edition, Chapter 139 (Liver Fibrosis and Cirrhosis)
Robbins, Cotran & Kumar Pathologic Basis of Disease, Chapter 18 (Chronic Liver Failure and Cirrhosis)
Robbins & Kumar Basic Pathology, Chapter 18 (Portal Hypertension)
Sleisenger and Fordtran's Gastrointestinal and Liver Disease

This is a shared conversation. Sign in to Orris to start your own chat.